EHR usage up, but specialists fail to provide info

More than two-thirds of U.S. primary care physicians now use electronic health records (EHRs), but less than one-fifth report that they routinely receive timely information from specialists or hospitals, according to a survey of physicians in the U.S. and nine other countries.

Related Videos

Related Content

Advertisement

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.

Related Content

Advertisement

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.